Neurogranin in CSF has been suggested as a biomarker of early synaptic loss and degeneration in Alzheimer’s disease and may be a useful predictor of disease progression [260]. The gene discussed is NRGN; the disease is early-onset autosomal dominant Alzheimer disease.